Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 2:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 797 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Celgene Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

2-part Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of CC-220 & Effect of Food on CC-220 in Healthy Subjects

NCT01733875
View directory record Official record
Conditions
Healthy
Interventions
CC-220 0.03 mg, CC-220 0.1 mg, CC-220 0.3 mg, CC-220 1 mg, CC-220 2 mg, Placebo, CC-220
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Oct 15, 2026, 2:39 PM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT02546986
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
CC-486, Pembrolizumab, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
10
States / cities
Glendale, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 15, 2026, 2:39 PM EDT
Completed Phase 2 Interventional Results available

Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas

NCT01730586
View directory record Official record
Conditions
Colorectal Cancer, Cancer of Gastrointestinal Tract
Interventions
Abraxane
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 15, 2026, 2:39 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer

NCT00988208
View directory record Official record
Conditions
Prostate Cancer
Interventions
Lenalidomide, Docetaxel, Prednisone, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,059 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
66
States / cities
Phoenix, Arizona • Sedona, Arizona • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Oct 15, 2026, 2:39 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer

NCT00479674
View directory record Official record
Conditions
Breast Cancer
Interventions
Abraxane, Bevacizumab, Carboplatin
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
4
States / cities
Charlotte, North Carolina • Concord, North Carolina • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2015 · Synced Oct 15, 2026, 2:39 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma

NCT02685826
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Durvalumab, Lenalidomide, Dexamethasone
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
7
States / cities
Birmingham, Alabama • Atlanta, Georgia • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2023 · Synced Oct 15, 2026, 2:39 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Rifampin and Efavirenz on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects

NCT03983239
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Fedratinib, Rifampin, Efavirenz
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2020 · Synced Oct 15, 2026, 2:39 PM EDT
Completed Phase 1Phase 2 Interventional Results available

PKC412 and 5-Azacytidine

NCT01202877
View directory record Official record
Conditions
Leukemia
Interventions
5-azacytidine, PKC412
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Oct 15, 2026, 2:39 PM EDT
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)

NCT02775903
View directory record Official record
Conditions
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Interventions
Azacitidine, Durvalumab
Drug · Biological
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
12
States / cities
New Haven, Connecticut • Washington D.C., District of Columbia • Gainesville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Oct 15, 2026, 2:39 PM EDT
Completed Not applicable Interventional Results available

A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis

NCT00890552
View directory record Official record
Conditions
Leukemia, Amyloidosis
Interventions
Lenalidomide, Melphalan, Dexamethasone
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Oct 15, 2026, 2:39 PM EDT
Terminated Phase 2 Interventional Results available

Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma

NCT01316523
View directory record Official record
Conditions
Non Hodgkin's Lymphoma
Interventions
Rituximab, Lenalidomide
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2024
U.S. locations
2
States / cities
Sacramento, California • Santa Rosa, California
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 15, 2026, 2:39 PM EDT
Completed Phase 2 Interventional Results available

Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer

NCT02317991
View directory record Official record
Conditions
Gastroesophageal Cancer
Interventions
nab-paclitaxel, ramucirumab
Drug · Biological
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
11
States / cities
Denver, Colorado • Fort Myers, Florida • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2022 · Synced Oct 15, 2026, 2:39 PM EDT
Active, not recruiting Phase 1 Interventional

Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma

NCT01829568
View directory record Official record
Conditions
Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 3 Follicular Lymphoma
Interventions
Ibrutinib, Lenalidomide, Rituximab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 15, 2026, 2:39 PM EDT
Completed Phase 2 Interventional

A Safety Study of ABI-007 for In-Stent Restenosis

NCT00093223
View directory record Official record
Conditions
Angina Pectoris, Coronary Artery Disease
Interventions
Paclitaxel Nanoparticle Albumin Bound
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 15, 2026, 2:39 PM EDT
Completed Phase 2 Interventional

Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide

NCT00162760
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis (IPF)
Interventions
Thalidomide
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years to 80 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 22, 2010 · Synced Oct 15, 2026, 2:39 PM EDT
Completed Phase 1 Interventional

A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)

NCT02966782
View directory record Official record
Conditions
Myelodysplastic Syndromes (MDS)
Interventions
venetoclax, azacitidine
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
10
States / cities
Tucson, Arizona • Aurora, Colorado • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 15, 2026, 2:39 PM EDT
Terminated Phase 1 Interventional

Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian Cancer

NCT01202890
View directory record Official record
Conditions
Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
Interventions
Lenalidomide, Liposomal Doxorubicin, Bevacizumab, Revlimid, Doxil, Avastin
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 8, 2014 · Synced Oct 15, 2026, 2:39 PM EDT
Completed Phase 2 Interventional Results available

5-Azacytidine Prior to Allogeneic Stem Cell Transplant in High Risk Myelodysplastic Syndrome

NCT00721214
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
5-azacytidine
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 2, 2016 · Synced Oct 15, 2026, 2:39 PM EDT
Completed Phase 1 Interventional

A Study Evaluating Potential Disease-Mediated Drug-Drug Interaction in Adult Participants With Active Eosinophilic Esophagitis Receiving Cendakimab

NCT05175352
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Cendakimab, CYP substrates
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
12
States / cities
Tucson, Arizona • Los Angeles, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 15, 2026, 2:39 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders

NCT02494258
View directory record Official record
Conditions
Hematologic Neoplasm, Neoplasms, Hematologic Malignancies
Interventions
CC-486
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
3
States / cities
Gainesville, Florida • Baltimore, Maryland • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 15, 2026, 2:39 PM EDT
Terminated Phase 1 Interventional

Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL

NCT00543114
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
Interventions
Lenalidomide, Fludarabine, Rituximab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 27, 2016 · Synced Oct 15, 2026, 2:39 PM EDT
Terminated Phase 1 Interventional

Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia

NCT04789655
View directory record Official record
Conditions
Leukemia, Myeloid
Interventions
CC-96191
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
8
States / cities
Birmingham, Alabama • Jacksonville, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 15, 2026, 2:39 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Ozanimod in Ulcerative Colitis

NCT01647516
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Ozanimod, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 73 Years
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
10
States / cities
Anaheim, California • La Jolla, California • Oceanside, California + 7 more
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 15, 2026, 2:39 PM EDT
Terminated Phase 1 Interventional

CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma

NCT04047303
View directory record Official record
Conditions
Astrocytoma, Glioblastoma
Interventions
CC-90010
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Tampa, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 5, 2024 · Synced Oct 15, 2026, 2:39 PM EDT